CD56 expression predicts response to Daratumumab-based regimens | Blood Cancer Journal nature.com/articles/s4140…

In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease. nature.com/articles/s4140…

Daratumumab-based quadruplet therapy for high risk transplant-eligible newly diagnosed myeloma. ⁦Natalie Callander⁩ ⁦Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰⁩ ⁦Robert Z. Orlowski⁩ ⁦Luciano J Costa⁩ #OpenAccess nature.com/articles/s4140…

Dr Vincent Rajkumar kicking of the spring ECOG-ACRIN Cancer Research Group meeting with a reminder of the Scientific Objectives of the myeloma committee. #eaonc Mike Thompson, MD, PhD, FASCO Natalie Callander

Join us today at 730pm eastern on Twitter Spaces where we will discuss updates in myeloma and answer your questions. Spaces #IMFmyelomaChat

This is going to be part of International Myeloma Foundation initiative featuring IMF CEO Yelak Biru

📰This study published by Blood Cancer Journal, elucidates not only the importance of disease biology but also the role of management prior to apheresis.
READ➡️tinyurl.com/3yb2tt76
#MYELOMA #MultipleMyeloma #bloodcancer #hematology #MedTwitter #Oncology #Cancer #Cancer Research

Risk stratification of #BCR_ABL #ALL based on #IKZF_Pos and #MRD assessment and need for #HCT

Nice read ⁦Blood Cancer Journal⁩

Refined risk stratification helps guiding transplantation choice in adult BCR::ABL1-positive acute lymphoblastic leukemia nature.com/articles/s4140…

Pub Alert 🚨 Francesca Cottini, MD (Francesca Cottini)
published 'CD56 expression predicts response to Daratumumab-based regimens' in Blood Cancer Journal.

nature.com/articles/s4140…

Myeloma Paper of the Day, April 30th, suggested by Robert Z. Orlowski
MD Anderson Cancer Center Blood Cancer Journal Paula Rodriguez-Otero PETHEMA
oncodaily.com/59340.html

#Cancer #MM #MyelomaPaperOfTheDay #OncoDaily #Oncology #Cancer Research

RAS mutations in myeloid malignancies. #OpenAccess nature.com/articles/s4140…

Refined risk stratification to guide transplantation choice in adult BCR::ABL1-positive acute lymphoblastic leukemia (ALL). nature.com/articles/s4140…

Emapalumab and ruxolitinib in patients with haemophagocytic Lymphohistiocytosis. nature.com/articles/s4140…

Rapid immune reconstitution with autologous, Blinatumomab Expanded T-cells (BET) in patients with indolent NHL or CLL. #Lymphoma nature.com/articles/s4140…

Dara-KRd and Dara-VRd for transplant-eligible NDMM with high cytogenetic risk. Inferior PFS with both quadruplets with >/= 2 HRCA #mmsm #bmtsm Natalie Callander Plasma Cell Pete Luciano J Costa Blood Cancer Journal nature.com/articles/s4140…

Here are all the drug approvals for relapsed multiple myeloma in 20 years. Bookmark it! Amazing! #MedTwitter

🔬 2024 Advancements in #MDS Classification: New research published in Blood Cancer Journal in April suggests integrating the 2022 ICC & WHO-2022 systems to improve MDS diagnosis & treatment.
👉 Read more about this research here: nature.com/articles/s4140…
#BloodCancer #MedicalResearch

Excited to share our latest study 'Induction of NK cell reactivity against acute myeloid leukemia by Fc-optimized CD276 (B7-H3) antibody' in Blood Cancer Journal. Congrats to Sylwia A. Stefańczyk Melly M and all contributors! 🎉 #AML #Leukemia #immunotherapy #ADCC

nature.com/articles/s4140…

🎉Excited to share my latest paper on NK cell reactivity against #AML with Fc-optimized CD276 antibody in Blood Cancer Journal!
Grateful for my supervisors’ guidance and colleagues’ collaboration. Melly M Translational Immunology #antibody #leukemia #ADCC #immunotherapy

The perspective comments on real world data published in Blood Cancer Journal by Aimaz Afrough Yi Lin Surbhi Sidana, MD Gurbakhash Kaur Larry Anderson,MD,PhD,FACP Shonali Midha, M.D. Hamza Hashmi Krina Patel Douglas W. Sborov MD MS Omar Nadeem et al.

nature.com/articles/s4140…